[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639759":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":11,"centralContacts":33,"locations":39,"responsibleParty":73,"collaborators":11,"id":75,"slug":11,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":76,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":11,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Oculis","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Privosegtor","EXPERIMENTAL",null,[13,14],"Drug: Privosegtor","Drug: Methylprednisolone",{"label":16,"type":17,"description":11,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR",[14,19],"Other: Placebo",[21,25,29],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Privosegtor (OCS-05) 3 mg\u002Fkg\u002Fday IV for 5 treatment days",[9],{"type":22,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Methylprednisolone","Methylprednisolone 1 g\u002Fday IV for 5 treatment days",[16,9],{"type":30,"name":16,"description":31,"armGroupLabels":32,"otherNames":11},"OTHER","0.9% sodium chloride (NaCl) solution IV for 5 treatment days",[16],[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Chief Development Officer","CONTACT","617-928-5886","info@oculis.com",[40,58],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Kahana Oculoplastic and Orbital Surgery","RECRUITING","Livonia","Michigan","48152","United States",{"type":48,"coordinates":49},"Point",[50,51],-83.35271,42.36837,{"lat":51,"lon":50},[54],{"name":55,"role":36,"phone":56,"phoneExt":11,"email":57},"Dr. Victoria Williams","248-800-1177","kcrc@mioculoplastics.com",{"facility":59,"status":42,"city":60,"state":61,"zip":62,"country":46,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Neuro-Eye Clinical Trials","Houston","Texas","77074",{"type":48,"coordinates":64},[65,66],-95.36327,29.76328,{"lat":66,"lon":65},[69],{"name":70,"role":36,"phone":71,"phoneExt":11,"email":72},"Mirna Maldonado","713-894-4393","Rtang@neuroeye.com",{"type":74,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100639759",false,"NCT07623668","Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research","A Randomized, Double-masked, Placebo-controlled Study Assessing the Efficacy and Safety of Privosegtor (OCS-05) in Patients With Optic Neuritis (ON)","PIONEER-1","Key Inclusion Criteria:\n\n* Adult men and women (aged 18 to 50 years) with the first episode of ON in the study eye, associated with unilateral visual loss.\n* Onset of visual loss symptoms in the previous 12 days before first administration of study treatment.\n\nKey Exclusion Criteria:\n\n\\- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety","ALL","18 Years","50 Years",{"count":86,"type":87},210,"ESTIMATED","INTERVENTIONAL",[90],"PHASE3","The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON).\n\nResearchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).",[93],"Optic Neuritis",[93,95,96,97,98,99,100,101,102,103,9,104],"ON","AON","Optic Neuropathy","Multiple Sclerosis","MS","Vision Loss","LCVA","Low Contrast Visual Acuity","Low Contrast Sensitivity","OCS-05","2026-06-29",{"date":107,"type":108},"2026-07-01","ACTUAL",{"date":110,"type":108},"2026-05-28",{"date":112,"type":87},"2028-12",{"name":5,"class":6},2]